BP 2.94


BP 2.94, or BP-294, also known as FUB-94, is a histamine H3 receptor agonist which was under development for the treatment of asthma, inflammation, pain, and peptic ulcers but was never marketed. It is taken orally.

Pharmacology

The drug functions as an orally active prodrug of (R)-α-methylhistamine, which in turn acts as a potent and selective agonist of the histamine H3 receptor. BP 2.94 has shown anti-inflammatory, antinociceptive, gastric anti-secretory, and sedative and hypnotic effects in animals. It has been found to increase slow [wave sleep] in animals, including dramatically so in cats.

Development

BP 2.94 was under development by Bioprojet. It reached Phases of [clinical research#Phase II|phase 2] clinical trials prior to the discontinuation of its development.